Topics

Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Solid Organ Transplantation

2019-09-18 03:27:35 | BioPortfolio

Summary

The purpose of this study is to test whether daratumumab, a drug that eliminates antibody-producing plasma cells, can effectively lower the level of preformed antibodies in patients awaiting solid organ transplantation. These preformed antibodies limit the number of donor hearts that are compatible for the patients. If daratumumab can effectively remove preformed, donor-specific antibodies, then highly allosensitized patients will have more compatible hearts to them, potentially decreasing transplant waitlist time and reducing mortality.

Study Design

Conditions

Allosensitization

Intervention

Daratumumab

Status

Not yet recruiting

Source

Stanford University

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-09-18T03:27:35-0400

Clinical Trials [110 Associated Clinical Trials listed on BioPortfolio]

A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

The main purpose of this study is to assess the safety of the combination of JNJ-63723283 and daratumumab (Part 1); to compare the overall response rate (ORR) in participants treated with ...

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab, compared with daratumumab alone, in participants with relapsed or ...

Short Course Daratumumab in Patients With Multiple Myeloma

The purpose of this study is to test the safety of short course Daratumumab in combination with lenalidomide and to find out what effects, if any, short course Daratumumab in combination w...

Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)

The goal of this clinical research study is to learn if daratumumab can help to control B- or T-cell acute lymphoblastic leukemia (ALL). The safety of daratumumab will also be studied.

A Pilot Presurgical Study of Daratumumab in Men With High-Risk Localized Prostate Cancer

The goal of this clinical research study is to learn about the safety and tolerability of giving Darzalex (daratumumab) to patients who have prostate cancer before having an already-schedu...

PubMed Articles [22 Associated PubMed Articles listed on BioPortfolio]

Association between Allosensitization and Waiting List Outcomes among Adult Lung Transplant Candidates in the United States.

Allosensitization may be a barrier to lung transplantation. Currently, consideration is not given to allosensitization when assigning priority on the lung transplant waiting list.

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.

The efficacy of daratumumab (DARA) both as a monotherapy and in combination with standard-of-care regimens in multiple myeloma (MM) has been established in clinical trials. This article presents a ret...

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Lenalidomide plus dexamethasone is a standard treatment for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. We sought to determine whether t...

Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis.

To investigate the activity and safety of daratumumab added to standard of care, and evaluate the relative efficacy of DRd versus DVMP and other regimens on survival endpoints for untreated myeloma, w...

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.

The anti-CD38 monoclonal antibody daratumumab is approved as a single agent for the treatment of patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior li...

Medical and Biotech [MESH] Definitions

None available.

More From BioPortfolio on "Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Solid Organ Transplantation"

Quick Search

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...


Searches Linking to this Trial